Patents by Inventor Olaf Wilhelm

Olaf Wilhelm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR ENRICHING EXOSOMES
    Publication number: 20230243850
    Abstract: The present invention relates to methods for producing an exosome enriched fraction from a sample. The method comprises the steps of contacting a first binding agent that specifically binds to the extra-vesicular part of Rab11 or a second binding agent that specifically binds to the extra-vesicular part of Rab4, or a combination thereof, to the sample under conditions allowing binding of said first binding agent and/or second binding agent to exosomes; and separating exosomes to which the first binding agent and/or the second binding agent is bound from the sample. Further provided are methods for diagnosing cancer and viral diseases, methods for quantifying and/or qualifying tumor-related and virus-related exosomes in a sample, methods for monitoring tumor growth and viral diseases. Also provided is a kit comprising means for carrying out the methods.
    Type: Application
    Filed: April 16, 2021
    Publication date: August 3, 2023
    Inventors: Olaf WILHELM, Gabriele SCHRICKER, Rudolph NAPIERALSKI, Percy KNOLLE, Bastian HOCHST, Charlotte FLYNN
  • Classifying a cancer disease using CAIX expression
    Patent number: 10620208
    Abstract: The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 14, 2020
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Paul Bevan, Barbara Fall, Pia Klöpfer
  • CAIX STRATIFICATION BASED ON CANCER TREATMENT
    Publication number: 20160002350
    Abstract: The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 7, 2016
    Applicant: WILEX AG
    Inventors: Olaf WILHELM, Paul BEVAN, Barbara FALL, Pia KLÖPFER
  • Joint bearing
    Patent number: 7891878
    Abstract: The invention relates to a spherical plain bearing, having an inner ring with a spherically curved outer surface and an outer ring having a spherically curved inner surface, a seal being arranged in a continuous groove in the outer ring. The seal has an annular support and rubs against the outer surface of the inner ring. The seal has two mutually spaced resilient sealing lips facing in opposite directions. The first sealing lip being oriented outwards and the second sealing lip being oriented inwards.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: February 22, 2011
    Assignee: Schaeffler KG
    Inventors: Harald Peschke, Olaf Wilhelm, Thomas Fickert
  • Adjuvant theraphy of G250-expressing tumors
    Patent number: 7691375
    Abstract: The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: April 6, 2010
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Sven Warnaar
  • Joint Bearing
    Publication number: 20080199113
    Abstract: The invention relates to a spherical plain bearing, having an inner ring with a spherically curved outer surface and an outer ring having a spherically curved inner surface, a seal being arranged in a continuous groove in the outer ring. The seal has an annular support and rubs against the outer surface of the inner ring. The seal has two mutually spaced resilient sealing lips facing in opposite directions. The first sealing lip being oriented outwards and the second sealing lip being oriented inwards.
    Type: Application
    Filed: June 22, 2006
    Publication date: August 21, 2008
    Applicant: SCHAEFFLER KG
    Inventors: Harald Peschke, Olaf Wilhelm, Thomas Fickert
  • Diagnostic and therapeutic use of antibodies against the urokinase receptor
    Patent number: 7399468
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: July 15, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Martin Mueller, Sybille Albrecht, Viktor Magdolen, Olaf Wilhelm, Manfred Schmitt, Nadja Harbeck
  • Urokinase inhibitors and uses thereof
    Patent number: 7342018
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: March 11, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jörg Stürzebecker, John Foekens, Verena Lutz
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7314863
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: January 1, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Adjuvant Theraphy of G250-Expressing Tumors
    Publication number: 20070207157
    Abstract: The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasising disease.
    Type: Application
    Filed: June 29, 2005
    Publication date: September 6, 2007
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Sven Warnaar
  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7208521
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: April 24, 2007
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Diagnostic and therapeutic use of antibodies against the urokinase receptor
    Publication number: 20070066798
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Application
    Filed: October 26, 2006
    Publication date: March 22, 2007
    Applicant: WILEX AG
    Inventors: Manfred Schmitt, Viktor Magdolen, Thomas Luther, Sybille Albrecht, Martin Muller, Olaf Wilhelm, Nadja Harbeck
  • Highly selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049344
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: May 23, 2006
    Assignees: Wilex Biotechnology GmbH, Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049460
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: May 23, 2006
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Cyclic peptidomimetic urokinase receptor antagonists
    Publication number: 20060105943
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Application
    Filed: December 30, 2005
    Publication date: May 18, 2006
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 7045504
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Buergle, Nils Potthoff, Niko Schmiedeberg
  • Selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050215642
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Application
    Filed: February 16, 2005
    Publication date: September 29, 2005
    Applicant: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jorg Sturzebecher, Olaf Wilhelm
  • Cyclic peptidomimetic urokinase receptor antagonists
    Patent number: 6906032
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: June 14, 2005
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Bürgle, Nils Potthoff, Niko Schmiedeberg
  • Highly selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050119348
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 2, 2005
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Cyclic peptidomimetic urokinase receptor antagonists
    Publication number: 20050101526
    Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.
    Type: Application
    Filed: December 22, 2004
    Publication date: May 12, 2005
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Horst Kessler, Markus Burgle, Nils Potthoff, Niko Schmiedeberg